A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group investigation

British Journal of Cancer

Volumn 84, Issue 1, 2001, Pages 11-18

  Estlin, E J ^a   Pinkerton, C R ^a   Lewis, I J ^a   Lashford, L ^a   McDowell, H ^a   Morland, B ^a   Kohler, J ^a   Newell, D R ^b   Boddy, A V ^b   Taylor, G A ^b   Price, L ^a   Ablett, S ^a   Hobson, R ^a   Pitsiladis, M ^c   Brampton, M ^c   Clendeninn, N ^d   Johnston, A ^d   Pearson, A D J ^a  

^a United Kingdom Children's Cancer Study Group   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Cancer Research Campaign Phase   (United States)

^d AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

Acute lymphoblastic leukaemia; Deoxyuridine; Methotrexate resistance; Pharmacokinetics

Indexed keywords

DEOXYURIDINE; NOLATREXED; THYMIDYLATE SYNTHASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; HUMAN; LYMPHOBLAST; MALE; MOUTH INFLAMMATION; NEUROECTODERM TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UNITED KINGDOM;

ACUTE DISEASE; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; ENZYME INHIBITORS; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MALE; NEOPLASMS; QUINAZOLINES;

EID: 17744372247     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1569     Document Type: Article

References (34)

1. Pediatric Phase I trial and pharmacokinetic study of piritrexim administered orally on a 5-day schedule
2. Inhibition of phosphoribosylaminoimadazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates
3. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates
4. Pediatric Phase I trial and pharmacokinetic study of trimetrexate
5. General Principles of Chemotherapy
6. A phase II trial of Thymitaq™ in patients with squamous cell carcinoma of the head and neck
7. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumours: A Collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group Trial
8. Pediatric Phase I drug tolerance: A review and comparison of recent adult and pediatric Phase I trials
9. European Community Commission notes for guidance: Good Clinical Practice for trials of Medicinal Products in the European Community
10. Initial clinical trial and pharmacokinetics of Thymitaq™ (AG337) by 10-day continuous infusion in patients with advanced solid tumours
11. A Phase I study of carboplatin in children with acute leukaemia in bone marrow relapse. A report from the Children's Cancer Group
12. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell
13. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphoblastic leukaemia and is associated with decreased reduced folate carrier expression
14. Folate-based thymidylate synthase inhibitors as anticancer drugs
15. The reduced folate methotrexate carrier and a membrane-associated folate binding protein as transport routes for novel antifolates: Structure-activity relationships
16. A comparison of two Phase I trial designs
17. The measurement of performance in childhood cancer
18. Enzymatic synthesis of the folylpolyglutamates
19. Tolerance to antineoplastic agents in children and adults
20. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukaemic effects in vivo
21. Simplified calculation of body-surface area
22. Clinical Pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion
23. A Phase I clinical study of the novel antifolate AG337 given by 5 day oral administration
24. Preclinical and Phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumours
25. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children
26. Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors
27. A Phase II trial of Thymitaq™ in patients with hepatocellular carcinoma
28. Thymidylate synthase inhibitors
29. Kinetic characteristics of ICI D1694: A quinazoline antifolate which inhibits thymidylate synthase
30. Design of thymidylate synthase inhibitors using protein crystal structures: The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones
31. AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo preclinical studies
32. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (> 50 chromosomes) B-lineage acute lymphoblastic leukaemia: A Pediatric Oncology Group Study
33. Randomised comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukaemia